Navigation Links
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
Date:7/22/2008

BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed its strategic direction to develop its existing portfolio of compounds and the company will actively seek to acquire additional compounds and opportunities through Merger & Acquisition activity.

The strategic review was triggered by a recent accumulation of a number of factors that impacted the commercial return for the phase 3 PATHWAY trial.

The trial is unlikely to meet the forecast patient recruitment timetable and further significant delays were expected due to:

-- slower than expected regulatory processes in China, Korea and Vietnam;

-- slower than expected initiation of clinical sites;

-- slower than expected recruitment of patients into active sites; and

-- the recent launch of a competitive phase 3 trial, assessing Bayer/Onyx Nexavar(R) in the same indication.

Due to a lack of a global partner willing to meaningfully develop and commercialise PI-88, the commercial opportunity is much less than previously expected. Without a significant global partner contributing, Progen will be less able to expand into additional indications and exploit all potential PI-88 commercial opportunities.

These aspects would have delayed market entry significantly and seriously impacted on the commercial return of the phase 3 PATHWAY trial.

The next step is that Progen will seek expressions of interest in PI-88, at a regional level, initially from amongst those parties that had entered into Non-Disclosure Agreements and Due Diligence on PI-88.

The PI-88 trial had been facilitated through external agencies, and had resulted in 23 sites being opened for patient recruitment and 12 patients from 5 recruitment centres having be
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
3. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Progen Announces PI-88 Phase 2 Lung Cancer Results
9. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical products ... results for the fourth quarter and fiscal year ended ... 2015 overview: , Revenues from continuing operations of ... last year,s comparable quarter, and $202.6 million for fiscal ... $0.50 for the fourth quarter, up 194% over last ...
(Date:4/30/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader ... restore failing hearts, said today it will participate in ... on Thursday, May 14. D. Keith ... an update on the company, beginning at 10:40 a.m., ... The presentation will be available through the conference ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
(Date:5/2/2015)... ProText Kinetic 2 is a set of ... Pro X. ProText Kinetic 2 features 40 animation ... Pro X . Easily create interactive text videos without ... ProText Kinetic 2. , Using ProText Kinetic is as easy ... Kinetic presets in the FCPX timeline. Playback the default ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured on ... features the latest and coolest technology products available to ... for NewsWatch, conducted the review and shared with viewers ... Music is an important part of people’s lives – ... the royal treatment. Peachtree Audio does just that with ...
(Date:5/2/2015)... TX (PRWEB) May 02, 2015 ... skin laxity issues of the face, neck and ... new concept with real potential for the success ... by the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s ... FACOG, FACS, ACGE, concluded that ThermiGyn’s temperature controlled ...
(Date:5/1/2015)... IDLife LLC, a health and wellness ... the addition of its newest partner and fitness celebrity, ... athlete, growing up in gymnastics and competitive diving, but ... a personal trainer and helping others achieve their fitness ... TV shows highlighting her stunning physique and unique training ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... The American Red Cross,announced today that J. ... of,Executive Vice President for the organization,s Biomedical Services., ... largest blood collection,organizations. Each year the American Red ... distributes around 9.5 million blood products to,patients at ...
... ARLINGTON, Va., Jan. 8 The American,Association for ... fraud announced today in another of a series of ... Services (CMS) on the same,subject. The Association continues to ... in the durable medical equipment,(DME) sector. At the same ...
... - Net revenue projected to grow 20 percent in 2008 ... milestones for the DPP-4 ... - EPS expected to grow 36 percent in 2008, ... 2007 guidance and reported its projected,financial guidance for 2008., PPD anticipates that ...
... Use May Be Associated with Reduced Cancer Risk ... be at lower risk for developing cancer, especially lung ... directly prevent cancer. , Laboratory studies have shown that ... observational studies has been inconsistent. , To investigate ...
... carriers , , TUESDAY, Jan. 8 (HealthDay News) -- Not ... show the same risk for developing breast cancer. , ... risk among families carrying the mutations, indicating that the ... factors. , "Risk among carriers varies considerably, and, if ...
... dialysis patients shows that although U.S. residents have the ... their prescription drugs are far less likely to take ... research from the University of Michigan School of Public ... that high out-of-pocket drug costs are only a partial ...
Cached Medicine News:Health News:American Red Cross Announces New Leader for Biomedical Services 2Health News:Medicare Anti-Fraud Measures are Way Overdue, Says Durable Medical Equipment Industry 2Health News:Medicare Anti-Fraud Measures are Way Overdue, Says Durable Medical Equipment Industry 3Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 2Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 3Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 4Health News:PPD Updates 2007 Forecast; Issues Financial Guidance for 2008 5Health News:Other highlights in the Jan. 8 JNCI 2Health News:Other highlights in the Jan. 8 JNCI 3Health News:Other highlights in the Jan. 8 JNCI 4Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 3Health News:Americans pay the most for prescription drugs and still don't take them 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: